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TRIALS

STUDY PROTOCOL

Open Access

Medication adherence and tolerability of
Alzheimer’s disease medications: study protocol
for a randomized controlled trial
Noll L Campbell1,2,3,4*, Paul Dexter3,5, Anthony J Perkins2, Sujuan Gao2,3,5, Lang Li6, Todd C Skaar7, Amie Frame2,3,
Hugh C Hendrie2,3,8, Chris M Callahan2,3,5 and Malaz A Boustani2,3,5

Abstract
Background: The class of acetylcholinesterase inhibitors (ChEI), including donepezil, rivastigmine, and galantamine,
have similar efficacy profiles in patients with mild to moderate Alzheimer’s disease (AD). However, few studies have
evaluated adherence to these agents. We sought to prospectively capture the rates and reasons for nonadherence
to ChEI and determine factors influencing tolerability and adherence.
Methods/design: We designed a pragmatic randomized clinical trial to evaluate the adherence to ChEIs among
older adults with AD. Participants include AD patients receiving care within memory care practices in the greater
Indianapolis area. Participants will be followed at 6-week intervals up to 18 weeks to measure the primary outcome
of ChEI discontinuation and adherence rates and secondary outcomes of behavioral and psychological symptoms
of dementia. The primary outcome will be assessed through two methods, a telephone interview of an informal
caregiver and electronic medical record data captured from each healthcare system through a regional health
information exchange. The secondary outcome will be measured by the Healthy Aging Brain Care Monitor and the
Neuropsychiatric Inventory. In addition, the trial will conduct an exploratory evaluation of the pharmacogenomic
signatures for the efficacy and the adverse effect responses to ChEIs. We hypothesized that patient-specific factors,
including pharmacogenomics and pharmacokinetic characteristics, may influence the study outcomes.
Discussion: This pragmatic trial will engage a diverse population from multiple memory care practices to evaluate
the adherence to and tolerability of ChEIs in a real world setting. Engaging participants from multiple healthcare
systems connected through a health information exchange will capture valuable clinical and non-clinical influences
on the patterns of utilization and tolerability of a class of medications with a high rate of discontinuation.
Trial Registration: Clinicaltrials.gov: NCT01362686
Keywords: Dementia, Adherence, Tolerability, Pharmacogenomics

Background
For the past 20 years, pro-cholinergic drugs such as
donepezil, galantamine and rivastigmine have been considered the standard of care for mild to moderate Alzheimer’s
disease (AD). These medications are not purported to alter
the natural history of the disease but they are believed to
offer symptomatic improvements, such as minimizing
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behavioral disturbances, representing one of the more difficult management problems for providers and caregivers of
patients with dementia [1,2]. In a recent Cochrane Systematic Review, Birks examined the results of 13 randomized,
double blind, placebo controlled trials of these agents [1].
The author concluded that these agents produced small improvements in cognitive function, activities of daily living,
and behavior. Additionally, nearly one in three patients
stopped treatment due to adverse effects such as nausea,
vomiting, and diarrhea. The review found few studies and
little evidence to suggest superiority of one of the agents
over another. Other recent meta-analyses reach similar
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conclusions [3-5]. In 2008, we completed a meta-analysis to
evaluate the efficacy of anti-dementia medications in reducing behavioral symptoms [5]. In comparison to placebo,
these medications reduced behavioral symptoms with effect
sizes of 0.10 to 0.16 on the Neuropsychiatric Inventory
(NPI) [6] depending on the degree of dementia severity.
In the United States, the branded prescription cost for
these drugs is approximately $2,500 to $3,500 per person
per year [7], though the recent introduction of generic
products to the market has significantly reduced the
cost. However, because of limited efficacy, costs, and
adverse effects, these drugs remain controversial among
clinicians [2,8]. In a study of physicians’ attitudes, Franz
et al. reported that 82% of prescribers had ambivalent or
negative impressions about prescribing cholinesterase
inhibitors [8]. Additionally, the United Kingdom National Health Service has debated whether to include
these agents on the national formulary due to concerns
about costs, safety, and effectiveness [9].
Two significant factors that likely contribute to the
low rate of prescribing pro-cholinergic drugs to
Alzheimer’s patients are the concern for drug-drug interactions and tolerability. Because of the frequent burden
of comorbidity of the older adult population, many
Alzheimer’s patients are routinely prescribed at least five
drugs, and many are prescribed even more, in an
attempt by providers to optimize disease state control
[10]. As the number of prescribed medications increases,
the frequency of daily administration requirements often
increases, requiring the patient and/or caregiver to
manage a more complex regimen. Many of these coadministered medications alter or compete for the activities of the hepatic drug metabolizing enzymes [11];
therefore, the pharmacokinetics of many metabolized
drugs may be highly variable. This is important for the
Alzheimer’s drugs donepezil and galantamine because
their primary route of elimination is hepatic metabolism
[12,13]. For example, paroxetine and bupropion are prescribed to Alzheimer’s patients [14] and are strong
inhibitors of CYP2D6, an enzyme important for the metabolism of donepezil and galantamine [15,16]. As
expected, in Alzheimer’s patients, the pharmacokinetics
of these drugs shows substantial variability (for example,
SD 39 to 51%) [17]. It may therefore be proposed that
concurrent medications, as well as genetic variations in
the drug metabolism enzymes, are a significant cause of
the inter-individual variability in efficacy and tolerability
of the Alzheimer’s drugs.
Comparative effectiveness research studies evaluate
alternative treatments or methods in the real-world
setting. Below we describe a study with a secondary aim
of understanding the role of drug-drug interactions and
pharmacogenomics in patients receiving therapy as routinely provided to AD patients to better understand the
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reasons for adherence and persistence to acetylcholinesterase inhibitors (ChEIs). We hypothesize that patientspecific clinical characteristics, including concomitant
medications, comorbidity, and pharmacogenomic characteristics will predict tolerability to certain ChEIs. We
will capture a broad array of phenotypic data that will be
used to help optimize the therapeutic and cost effectiveness of these drugs.

Methods/design
Ethical approval

The study has been approved by the Institutional Review
Board (IRB) of Indiana University Purdue University
Indianapolis, as well as each participating healthcare
system. Approval for enrollment in the study requires
informed consent provided by the potential participant’s
legally authorized representative.
Study location and population

Participants are enrolled from one of four healthcare
systems within the metropolitan Indianapolis area. These
healthcare systems include Wishard/Eskenazi Health,
Indiana University Health, St. Vincent Health, and
Community Health Network systems. Each memory care
practice within these healthcare systems provides services for a standardized evaluation of cognitive health,
including comprehensive neuropsychologic testing, and
other necessary laboratory and imaging parameters
recommended for the diagnosis of cognitive impairment
and dementia. A sample representation of the eligible
study population, those aged 65 years and older, from all
collaborating healthcare systems is provided in Table 1.
Study design

The design adopted in this study is a prospective, randomized open-label clinical trial intended to compare
adherence to and tolerability of the three ChEIs
approved for treatment of probable AD. The study will
include an assessment of the primary and secondary
Table 1 Demographic description of older adult
population within local healthcare systems representing
the Indianapolis Discovery Network for Dementia
Variable

IDND Health Care Systems

Number aged ≥ 65 years

99,574

Number of annual outpatient visits

345,991

Mean age, yrs

74.8

African American, %

16.6%

Female, %

60.0%

ICD-9 diagnosis of dementia, %

3.4%

ICD-9 diagnosis of diabetes mellitus, %

11.6%

ICD-9 diagnosis of hypertension, %

29.6%

IDND, Indianapolis Discovery Network for Dementia.
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outcome variables at baseline and weeks 6, 12, and 18.
Baseline interviews will be conducted during the clinic visit
in the memory care practices at the time of initiation of
the ChEI, while follow up assessments will be conducted
over the telephone. We hypothesize that clinical and
pharmacogenomic characteristics will explain differences
in tolerability among the three FDA-approved medications.
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provide permission to participate or would not meet
inclusion criteria, our study anticipates enrolling the
targeted 300 patients, with each practice contributing
approximately 75 participants. Enrolled subjects will be
followed for 18 weeks. Thus, we anticipate an enrollment rate of four to five subjects per month per memory
care practice or approximately one subject per week per
memory care practice (Figure 1).

Eligibility and enrollment

Eligible participants in this study will include those diagnosed with possible or probable AD within a memory
care practice of the four healthcare systems within central Indiana. Complete eligibility criteria require (1) the
provider’s intent to initiate therapy with a ChEI; (2)
agreement from a caregiver to complete the study outcomes assessments; (3) access to a telephone, and (4)
the ability to understand English to complete survey outcome assessments. Although the intended target population is comprised of those deemed by the physician as
appropriate for initiation of a ChEI, prior exposure to
this class of medications is not a contraindication for
eligibility. The study will not enroll subjects with an
appropriate diagnosis who are currently receiving treatment with a ChEI. In this pragmatic study, initiation of
the a ChEI is at the discretion of the clinicians at each
study cite. Exclusion criteria for study eligibility are simply those who have had a prior adverse drug event from
one of the study medications, which resulted in the clinician’s decision to avoid another trial of a ChEI.
We are aware from our past work that passive enrollment techniques (written flyers or posters, media advertisements, provider referral) have limited effectiveness.
Recognition of these enrollment barriers are an important part of the genesis of the Indianapolis Discovery
Network for Dementia (IDND) [18]. Effective enrollment
requires the presence of research personnel within each
of the clinics and direct access to patients in collaboration with the memory care providers and leadership.
To accomplish this, a study research assistant is invited
into each memory care practice to obtain informed consent from each eligible patient and/or an informal caregiver for study participation. The research assistant is
also responsible for conducting the telephone interviews
that constitute the outcome assessments.
Among the four participating practices, there are 12
half-day clinic sessions per week. In each half-day session, providers care for approximately one to two new
patients and four to five established patients. Thus, over
an 18-month period, we expect approximately 1,500
potentially eligible patients, including both new and
established patients. Based on IDND data, we forecast
that one third of these patients (n = 500) would have a
diagnosis of possible or probable AD [19]. Estimating
that 40% of the targeted patients could not or would not

Randomization

The randomization process will allocate participants to one
of three ChEIs, donepezil, rivastigmine, or galantamine,
and will be stratified by location. A computer-generated
randomization scheme is implemented in REDCap, the
Research Electronic Data Capture web-based system for
data collection available to the Clinical and Translational
Science Institutions (CTSI) and is accessible online. All
participating memory care practices have agreed to follow
the randomization protocol for patients participating in
this comparative tolerability study. Because the class of
medications studied in this trial is FDA-approved, none of
the allocation assignments represents experimental therapy
and no patients will be allocated to placebo.
Description of the intervention

The study intervention is limited to the initial treatment
allocation, determined by the randomization method
described above. Beyond the initial treatment selection,
the study will use a natural treatment and management
design. The memory care practice physicians will make
determinations about initial drug dosage and any dosage
changes and the timing of those changes. These physicians will also make the determination about whether to
switch to a different ChEI, add memantine, or any other
agent as needed on an individualized basis. We will, of
course, monitor the frequency and content of such
changes in the natural course of patient care throughout
the 18-week duration of the study.
Because each study site required approval through
each respective institutional review board, each study
site opened enrollment at various times. Following 12
months of enrollment, six months of which included
active enrollment at all study sites, a total of 80 participants have been enrolled and randomized into the study.
Table 2 provides demographic data for the population
completing the randomization process.
Evaluation/assessment parameters
Clinical data repository and clinical informatics tools

For more than 40 years, researchers at the Regenstrief
Institute (Indianapolis, IN) have developed and operated a
massive clinical informatics infrastructure, the Regenstrief
Medical Record System (RMRS) [20]. Now a robust, operational health information exchange, this informatics
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Older adult diagnosed with probable
Alzheimer’s disease at a participating
Memory Care Practice
N=500

Excluded due to:
Inclusion / exclusion criteria
Refusal
Other
Consent and Baseline assessment
N=300

Randomization by Patient
Stratified by Memory Care Practice

Allocated to donepezil
N=100

Allocated to rivastigmine
N=100

Allocated to galantamine
N=100

Follow-up assessment at 6, 12, and 18 weeks

Figure 1 COMparative Effectiveness research Trial of Alzheimer’s disease drugs (COMET) study planned enrollment flowchart.

effort created the Indiana Network for Patient Care
(INPC), which serves to aggregate electronic medical
record data from multiple clinical practices, laboratories,
imaging centers, pharmacies, the local and state health
departments and Indiana Medicaid in order to provide
effective clinical care, reduce redundancies, improve
healthcare quality and efficiency and reduce cost.
INPC participants deliver registration records (demographics), laboratory data, emergency department,
inpatient and outpatient encounter data including freetext chief complaint, and coded diagnoses and procedures (including length of stay) for hospital admissions
and emergency department visits. Some participants also
deliver pathology, pharmacy, and vital signs data. Today,
the INPC receives and processes clinical data from over
30 hospitals with 24 additional hospitals in process
located across the state, local laboratories and imaging
centers, and a few large group practices closely tied to
hospital systems. The INPC also currently gathers clinical data for a number of commercial payers, including
medication claims data for those receiving care within
the INPC institutions as provided by Surescripts™.
Table 3 summarizes data contributed to INPC by each
healthcare system participating in the COMET study. A
comprehensive and updated list of all contributing
healthcare organizations can be found at www.ihie.org/
Solutions/indiana-network-for-patient-care.php [21].
Architecturally, the system standardizes all clinical
data as it arrives at the INPC vault; laboratory test

results are mapped to a set of common test codes with
standard units of measure for patient care, public health
and research purposes. Each institution has the same file
structure in the Regenstrief system and shares the same
term dictionary, which contains the codes, names (and
other attributes) for tests, drugs, coded answers, et
cetera. INPC allows physicians working in an emergency
department and within other hospital settings in any of
the participating hospitals to view a patient’s previous
care information from all participating institutions as a
single virtual record. INPC is a centrally managed federated clinical data repository that supports a variety of
services. Currently this system is being used to provide
clinical services, research data, quality reporting, public
health reporting and other functions.
Data collection

Data collection for this study will be generated from two
sources. First, a research assistant will complete a
telephone-based survey at baseline, 6, 12, and 18 weeks.
The telephone survey will include a medication assessment and other cognitive and behavioral assessments as
described below. The research assistants will be blinded
to the randomization allocation and will capture studyrelated adverse events reported by the caregiver as well
as the actions taken in response to the adverse events.
All other data will come from the enhanced health information technology infrastructure of the INPC as described above.
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Table 2 Demographic description of the COMET study
population
Overall

Table 3 Summary of contributed data capabilities of the
Indiana Network for Patient Care (IDND)
Data Type

(n = 80)

Community
Health
System

Indiana
University
Health

St.
Vincent
Health

Wishard/
Eskenazi
Health System

Admission/
discharge

X

X

X

X

Emergency
Department

X

X

X

X

Gender, % (number)
Male

23.8 (19)

Female

76.2 (61)

Ethnicity, % (number)
Hispanic
Not Hispanic

1.3 (1)
98.7 (77)

Race, % (number)

IDND facilities participating in COMET study and
providing data to INPC

Clinic visit

X

X

X

X

Text reports

X

X

X

X

African American

41.2 (33)

Laboratory

X

X

X

X

White

58.8 (47)

Radiology

X

X

X

X

Transcription

X

X

X

Education, % (number)
Less than HS

14.1 (11)

Cardiology

X

Some HS

20.5 (16)

EKG

X

HS Graduate

32.1 (25)

Other

X

Some college

33.3 (26)

Marital Status, % (number)
Married

45.6 (36)

Widowed

39.2 (31)

Other

15.2 (12)

Age, mean (SD)

81.0 (8.1)

CG relation to patient, % (number)
Spouse

32.9 (26)

Daughter

41.8 (33)

Son

10.1 (8)

Other

15.2 (12)

How often CG sees patient, % (number)
Daily

81.0 (64)

Weekly

16.5 (13)

Several times/month

1.3 (1)

Several times/year

1.3 (1)

HS, high school; CG, caregiver.

Primary outcome
Discontinuation and adherence rates

The purpose of this study is not to establish efficacy of
the three medications for the indication of Alzheimer’s
disease. Each of these medications already has FDA approval for AD with established efficacy parameters. The
primary outcome measure is therefore the tolerability
and discontinuation rate among the three medications.
Tolerability will be assessed through a structured telephone interview conducted at 6, 12, and 18 weeks. Based
on previous systematic reviews, the rate of discontinuation of ChEIs is reportedly in the range of 30% by 12
weeks compared with placebo [1]. We will determine
the approximate date and reason for discontinuation by

X
X

X
X

For current and comprehensive list, visit: www.ihie.org/Solutions/indiananetwork-for-patient-care.php. EKG, electrocardiogram.

informal caregiver reports through the telephone-based
interview at 6, 12, and 18 weeks. Any reason for discontinuation will be recorded, including adverse effects and
cost.
Medication utilization

During active use of the study medication, rates of medication discontinuation and adherence will be assessed
through electronic dispensing and claims records received
from participating pharmacies and payer sources within
INPC. For each patient we will complete a record of all
subsequent medications used over the 18-week observation period. Prescription records for patients enrolled in
the trial will be reviewed using the INPC databases to
evaluate the use of psychotropic medications such as anticholinergic, antidepressant, anxiolytic, and antipsychotic
agents. These psychotropic medications will be categorized
based on the American Hospital Formulary Service system
criteria into antidementia (including cholinesterase inhibitors or memantine), antipsychotic, antiepileptic, antidepressant, and anxiolytic agents. We will categorize the
anticholinergic activities of each drug into definite or possible anticholinergic activities based on the author’s prior
work [21-24].
Secondary outcome measures
Neuropsychiatric inventory (NPI)

The NPI has been adopted by the Alzheimer’s Disease
Cooperative Studies (ADCS) investigators to obtain information on the presence of psychopathology in behavioral areas including delusions, apathy, hallucinations,
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disinhibition, agitation, depression, aberrant motor behavior, anxiety, night-time behavior, and euphoria. Possible scores range from 0 to 144. The inventory is
administered by the interviewer to a patient/participant’s
caregiver. The NPI can be used to assess changes in the
patient’s behavior over the past month or other specified
time intervals. If the caregiver reports the presence of
psychopathology, there are follow-up questions to assess
frequency, severity, and the level of caregiver distress
due to the behavior. Thus, the instrument is specifically
designed to also measure caregiver distress (possible
scores range from 0 to 60). The administration time is
about 20 minutes. The test has excellent reliability and
validity [6,25].
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Process of care, health care, and mortality

The study will record sociodemographic characteristics and
comorbid conditions for each patient through electronic
medical records captured by the INPC. Sociodemographic
status will be captured in part by capturing insurance provider. As stated previously and in Table 3, the electronic
medical record provides access to diagnoses, outcomes of
diagnostic testing, discharge summaries, and medications.
Through the available data collection systems, this study
will track multiple processes of care measures including all
visits to inpatient, outpatient, and emergency department
visits. In addition to the healthcare systems included in this
study, the INPC allows us to track hospitalization and acute
care visits from approximately 58 facilities throughout the
region and state of Indiana.

The Healthy Aging Brain Care (HABC) Monitor

Using a consortium of pilot funding from the NIA-funded
IU Roybal Center, the NIMH-funded Interventions and
Practice Research Infrastructure Program, and industry, a
local group of investigators developed a clinical tool with
a simple, user-friendly assessment to aid in the diagnosis
and management of dementia symptoms. The initial content of the HABC Monitor was established during a
retreat of 22 multidisciplinary experts in dementia care including representatives from IDND. The HABC Monitor
is designed to be completed by the patient, a family caregiver, or a professional caregiver to provide an overall assessment of current symptoms due to dementia (as well as
a measure of caregiver stress). The current HABC
Monitor includes 32 items covering four relevant clinical
domains of dementia symptoms: cognition, function, behavioral/psychological symptoms, and caregiver burden.
Each item has four categories of responses that assess the
frequency of the target problem in the past two weeks,
and was designed with the capability of measuring change
over time [26]. The HABC Monitor takes about five minutes to complete. The current HABC Monitor has two
versions, a caregiver version and a self-report version.
Notably, the instrument is specifically designed for practical application in real-world clinical practice. It is also
designed to facilitate electronic capture and longitudinal
tracking of these data. The HABC Monitor demonstrated
good internal consistency (0.73 to 0.92), test-retest reliability, construct validity indicated by correlations with the
caregiver-reported NPI total score and NPI caregiver distress score, sensitivity to three-month change compared
to NPI reliable change groups, and known-groups validity
indicated by significant separation of Mini-Mental Status
Examination (MMSE) severity groups and clinical diagnostic groups [26]. Although not designed as a screening
study, there was preliminary evidence for good operating
characteristics, according to area under the receiver operator curve (AUROC) with respect to gold standard clinical
diagnoses, relative to MMSE or NPI [26].

Pharmacogenomics exploratory analysis
Sample collection

Ethylenediaminetetraacetic acid (EDTA) blood samples are
collected at two time points, prior to starting treatment,
and at any follow-up appointment within the 18-week
study with a minimum of one month of separation
between samples. Specimens are centrifuged at room
temperature within one hour of collection and plasma is
stored at −80°C. DNA extraction is carried out by standard
methods. For improved quality control all procedures are
automatically captured and time stamped in an electronic
tracking system using barcodes. All of the data are stored
in a Web-based biospecimen application originally codeveloped by the National Cancer Institute. This application not only tracks all procedures performed on a
specimen, and the exact location and availability of specimens across individual research projects, but also links all
experimental data acquired from these biospecimens.
Pharmacogenomic characterization

To explore the possible mechanisms that contribute to
the efficacy and tolerability of donepezil, rivastigmine,
and galantamine, we will conduct a pharmacogenomic
analysis that focuses on the phase I hepatic metabolism
of these drugs. Since the elimination of donepezil and
galantamine are substantially dependent on hepatic metabolism by the cytochrome P450 2D6 and 3A4/3A5 enzymes, we will determine the activity status of each
participant’s CYP2D6, CYP3A4, and CYP3A5 enzymes.
The specific alleles tested will be CYP2D6: (*3, *4, *5, *6,
*9 nonactive alleles), and (*10, *17, *29, and *41; reduced
activity alleles); CYP3A4: *1B; CYP3A5: *3, *6, and *7
alleles [27-30]. Collectively, these alleles make up >95% of
the known functional variants relevant to the hepatic metabolism of the class of acetylcholinesterase inhibitors.
Since genetic variants in the ApoE gene have been associated with altered susceptibility to Alzheimer’s disease, and
may confer different response to the approved drugs, we
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will also determine the ApoE status for the ApoE ε2, ε3,
and ε4 alleles. We will determine if there is a main effect of
the ApoE genotype on tolerability, as well as include it as a
covariate in the analysis of the associations with the
CYP450 genotypes. Since the hypothesis for the association
between CYP450 genotypes and drug effects is through the
genotype’s effects on drug pharmacokinetics, the study will
also measure the drug concentrations in each participant’s
plasma. Drug concentrations will be determined by the Indiana University Clinical Pharmacology Analytical Core
Laboratory and will use the second sample collected. We
expect that the CYP450 poor metabolizers will have higher
drug concentrations, and thus more side effects and, consequently, a lower rate of adherence and persistence.
Planned analysis

Baseline characteristics of the enrolled subjects will be
compared among the three randomized groups. Any imbalances between groups will be used as covariates in subsequent analyses to reduce potential bias. All statistical
analysis will be performed using a combination of SAS
(SAS version 9.3, SAS Institute Inc. Cary, NC, USA) and
the open-source software R (Version 2.15.2012).
Primary analyses

To compare the primary outcome of discontinuation rates
of the three study medications (donepezil, rivastigmine,
galantamine) at 6, 12, and 18 weeks, we will use a generalized linear mixed model with a logit link for the binary
outcome with patients as random effects. The primary
predictors of interest include fixed effects of time, medication, and time-by-medication interaction, stratified by
study site. Variables found to have significant mean differences between groups at baseline will be added to the
basic model to see if the results remain unchanged. These
analyses will be corroborated with Cox regression analyses
to predict the time to discontinuation of the assigned
medication as reported at the follow up interviews.
To test the difference in the outcome of medication
adherence, we will compare the adherence of the randomly assigned medication for each patient using the
number of doses dispensed over the 18-week follow up
period divided by the number of days of follow up. Time
to discontinuation will also be compared between the
three randomized study groups. For count data of each
medication, we will use a log-linear model to compare
the amount used among the three randomized groups,
using similar covariates to those for modeling medication discontinuation.
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models to account for the repeated measurements as a
function of the randomized group, time, and other covariates, with patients as random effects. The group-bytime interaction is of primary interest. The health care
utilization measures for the study period will be compared among groups with nominal logistic regression
with group as the primary variable of interest and other
covariates as appropriate.
To examine the effects of genotypes, our initial investigation found that the donepezil metabolism pathway is
CYP2D6, and the galantamine metabolism pathway is
CYP3A4/5, while rivastigmine lacks a dominant metabolic pathway. CYP2D6 and CYP3A4/5 have many
non-functional or reduced function alleles; similarly,
many medications that may be used concomitantly by
study subjects may inhibit the relevant hepatic enzymes.
Study subjects will be classified as a poor metabolizer
for CYP2D6 or CYP3A4/5 if he/she either has a nonfunctional allele or takes a strong CYP2D6 or CYP3A4/5
inhibitor, respectively. Extensive metabolizers include all
others without such a variance. The binary variables of
poor metabolizer/extensive metabolizer and their interactions with the assigned medications will be added to
the models for the discontinuation of and adherence to
the assigned medications. If the estimated betweengroup differences in discontinuation or adherence are
reduced by the inclusion of metabolic category, then
some of the patients’ variable acceptance of these medications can be attributable to their genotypes. Similarly,
correlations between pharmacokinetic levels for each
study drug and relevant covariates (genetics, comedications, and other demographic social variables)
will be analyzed within each drug with log-linear
regression.
Sample size and power calculations

We made an assumption that donepezil has 15% discontinuation rate by 18 weeks (conservatively low based on
prior literature) [1], and rivastigmine and galantamine
have 35% discontinuation rate, then the study will have
88% power to detect the difference between donepezil
and each of the other two medications at two-tailed 5%
significance. If rivastigmine and galantamine have discontinuation rates of 30%, then we will have 79% power
to detect the difference between donepezil and these
medications combined. The power for detecting significant genotype effects will be low, but the analyses as
proposed will suggest whether it is worthwhile to pursue
the hypothesis that genotypes and protein signaling predict the tolerability of the different study medications.

Secondary analyses

The NPI collected at each interview and biospychosocial
assessments captured by the HABC Monitor at multiple
time points will be incorporated into mixed effect

Limitations

Although the study has several strengths, some limitations are worth noting. First, participant selection is
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expected to be consistent with the FDA-approved use of
the study medications, which includes a diagnosis of
probable AD. Such diagnoses may vary by practitioner
and result in a heterogeneous mixture of participants.
However, because the primary outcome and the duration
of the study are focused on tolerability and not efficacy,
the impact on generalizability should not be significantly
compromised. Second, because electronic data is contributed from multiple institutions, certain variables may
not be available for analysis. In prior work with data
from INPC institutions, missing data complicates comprehensive evaluation of either study outcomes or relevant covariates. However, this particular study combines
electronic data collection with human interactions
through telephone interviews to supplement potentially
missing data. Another limitation within the electronic
database may be highlighted in the use of pharmacy
dispensing or claims data as a measure of medication
exposure and adherence. Although the use of dispensing
and claims data allows for an objective measure of medication exposure free from recall bias, there are some
limitations to this data source. Notably, such data often
include only prescription medications and those
included in a participating plan formulary, potentially
missing medications not covered by a pharmacy benefit
plan. Use of pharmacy dispensing or claims data also
assumes that participants consume the medication as
directed. Lastly, the use of caregiver reports to evaluate
symptoms of dementia may minimize the true rate of
adverse events or dementia symptoms. This may complicate the comparison of results to other studies, however
caregiver reporting of adverse events will be consistently
reported within this study.

Discussion
This study contains several unique features that will
contribute to our knowledge of the ChEI’s in the real
world. First, we engaged the specialty care practices
located within a regional health information exchange to
acquire a representative mix of the population, including
patients of all races and income levels in a large
Midwestern city. In so doing we are able to study populations poorly represented in previous dementia studies.
Additionally, by using a multi-site approach of healthcare
systems involved in a health information exchange we are
able to supplement data capture in the study with clinical
data recorded in each electronic medical record. Third, our
study objectives offer a unique opportunity to study relevant clinical and non-clinical influences on utilization of
CHEI’s in a population with a high rate of discontinuation.
The design and outcomes assessed in this randomized
trial will provide useful information regarding the realworld use, tolerability, and persistence with ChEI’s among
older adults diagnosed with probable AD. Supplementing
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electronic healthcare utilization data with telephone interviews provides a wide array of relevant clinical and nonclinical variables to better understand the management of
dementia in real world memory care practices. This study
also has the potential to advance theories of tolerability
among participants using novel covariates that may predict clinical outcomes and translate to future scientific
work within this vulnerable population.

Trial status
At the time of manuscript submission, the study has
been actively enrolling participants for approximately
two years, with study sites initiating enrollment procedures as IRB approval was granted. Therefore, sites have
been actively enrolling subjects between 17 and 24
months. During this enrollment period, a total of 140
subjects have been enrolled, 104 have completed follow
up at six weeks and 81 have completed follow up at the
18-week study endpoint. To date, completion of baseline
interviews has occurred in 96% of enrolled participants
and 87% of the 18-week interview, indicating a high rate
of success in capturing study-related endpoints throughout the follow up period.
Abbreviations
AD: Alzheimer’s disease; ADCS: Alzheimer’s disease cooperative studies;
AUROC: area under the receiver operator curve; ChEI: acetylcholinesterase
inhibitors; CTSI: Clinical and translational science institutions;
EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent
assay; HABC: Healthy aging braincare; IDND: Indianapolis discovery network
for dementia; INPC: Indiana network for patient care; IRB: Institutional review
board; MMSE: Mini-mental status examination; NPI: Neuropsychiatric
inventory; REDCap: Research electronic data capture; RMRS: Regenstrief
medical record system.
Competing interests
The authors declare that they have no competing interests. Neither the
funding agency nor any outside organization had a role in study design or
manuscript preparation.
Authors’ contributions
All authors have read and approved the manuscript. All authors were
involved in study design and manuscript development.
Acknowledgements
The trial is funded through the Agency for Healthcare Research and Quality
R01HS019818-01. The funding agency had no role in the development of
the study design, collection, analysis, interpretation of data, manuscript
development, or the decision to submit this manuscript for publication. The
authors would like to acknowledge the following providers and employees
of the memory care practices assisting with subject identification and
enrollment: Health: Patrick Healey, MD; Diane Healey, MD; Vijaya Sirigirireddy,
MD; Jenny Allbright, RN, BSN, CCM; Indiana Alzheimer’s Disease Center:
Martin Farlow, MD; Community Health Network: Margaret Campbell, ANP,
GNP; Azita Chehresa, MD; Indiana University Health: Eugene Lammers, MD;
Kristine Lieb, MD; Kofi Quist, MD.
Author details
1
Department of Pharmacy Practice, Purdue University School of Pharmacy,
410 West 10th Street, West Lafayette, IN, USA. 2Indiana University Center for
Aging Research, Indianapolis, IN, USA. 3Regenstrief Institute, Inc., Indianapolis,
IN, USA. 4Wishard Health Services, Indianapolis, IN, USA. 5Department of
Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
6
Department of Medical and Molecular Genetics, Indiana University School of

Campbell et al. Trials 2013, 14:125
http://www.trialsjournal.com/content/14/1/125

Medicine, Indianapolis, IN, USA. 7Division of Clinical Pharmacology,
Department of Medicine, Indiana University School of Medicine, Indianapolis,
IN, USA. 8Department of Psychiatry, Indiana University School of Medicine,
Indianapolis, IN, USA.
Received: 13 November 2012 Accepted: 10 April 2013
Published: 4 May 2013
References
1. Birks J: Cholinesterase inhibitors for Alzheimer’s disease. Cochrane
Database Syst Rev (Online) 2006, 1:CD005593.
2. Hinton L, Franz CE, Reddy G, Flores Y, Kravitz RL, Barker JC: Practice
constraints, behavioral problems, and dementia care: primary care
physicians’ perspectives. J Gen Intern Med 2007, 22:1487–1492.
3. Trinh NH, Hoblyn J, Mohanty S, Yaffe K: Efficacy of cholinesterase
inhibitors in the treatment of neuropsychiatric symptoms and functional
impairment in Alzheimer disease: a meta-analysis. JAMA 2003,
289:210–216.
4. Sink KM, Holden KF, Yaffe K: Pharmacological treatment of
neuropsychiatric symptoms of dementia: a review of the evidence. JAMA
2005, 293:596–608.
5. Campbell N, Ayub A, Boustani MA, Fox C, Farlow M, Maidment I, Howard R:
Impact of cholinesterase inhibitors on behavioral and psychological
symptoms of Alzheimer’s disease: a meta-analysis. Clin Interv Aging 2008,
3:719–728.
6. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA,
Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment
of psychopathology in dementia. Neurology 1994, 44:2308–2314.
7. RedBook: Thomson Reuter’s Database for Average Wholesale Pricing. New
York, NY. [http://www.redbook.com/redbook/online/] Accessed March 20,
2011.
8. Franz CE, Barker JC, Kravitz RL, Flores Y, Krishnan S, Hinton L: Nonmedical
influences on the use of cholinesterase inhibitors in dementia care.
Alzheimer Dis Assoc Disord 2007, 21:241–248.
9. Kmietowicz Z: NICE proposes to withdraw Alzheimer’s drugs from NHS.
BMJ Clinical research ed 2005, 330:495.
10. Schubert CC, Boustani M, Callahan CM, Perkins AJ, Carney CP, Fox C,
Unverzagt F, Hui S, Hendrie HC: Comorbidity profile of dementia patients
in primary care: are they sicker? J Am Geriatr Soc 2006, 54:104–109.
11. Indiana University School of Medicine/Department of Medicine [Internet]:
P450 Drug Interaction Table. Indianapolis. c2009 updated 2012 January 25;
cited 2010 Feb 16]. Available from [http://medicine.iupui.edu/clinpharm/
DDIs/table.aspx]
12. Mannens GS, Snel CA, Hendrickx J, Verhaeghe T, Le Jeune L, Bode W, van
Beijsterveldt L, Lavrijsen K, Leempoels J, Van Osselaer N, Van Peer A,
Meuldermans W: The metabolism and excretion of galantamine in rats,
dogs, and humans. Drug Metab Dispos 2002, 30:553–563.
13. Tiseo PJ, Perdomo CA, Friedhoff LT: Metabolism and elimination of 14Cdonepezil in healthy volunteers: a single-dose study. Br J ClinPharmacol
1998, 46(Suppl 1):19–24.
14. Li L, Yu M, Jason RD, Shen C, Azzouz F, McLeod HL, Borges-Gonzales S,
Nguyen A, Skaar T, Desta Z, Sweeney CJ, Flockhart DA: A mixture model
approach in gene-gene and gene-environmental interactions for binary
phenotypes. J Biopharm Stat 2008, 18:1150–1177.
15. Bachus R, Bickel U, Thomsen T, Roots I, Kewitz H: The O-demethylation of
the antidementia drug galanthamine is catalysed by cytochrome P450
2D6. Pharmacogenetics 1999, 9:661–668.
16. Varsaldi F, Miglio G, Scordo MG, Dahl ML, Villa LM, Biolcati A, Lombardi G:
Impact of the CYP2D6 polymorphism on steady-state plasma
concentrations and clinical outcome of donepezil in Alzheimer’s disease
patients. Eur J Clin Pharmacol 2006, 62:721–726.
17. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L,
Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S,
Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA: CYP2D6 genotype,
antidepressant use, and tamoxifen metabolism during adjuvant breast
cancer treatment. J Natl Cancer Inst 2005, 97:30–39.
18. Boustani MA, Frame A, Munger S, Healey P, Westlund J, Farlow M, Hake A,
Austrom MG, Shepard P, Bubp C, Campbell NL, Dexter P: Connecting
research discovery with care delivery in dementia: the development of
the Indianapolis Discovery Network for Dementia. Clin Interv Aging 2012,
7:509–516.

Page 9 of 9

19. Boustani MA, Sachs GA, Alder CA, Munger S, Schubert CC, GuerrieroAustrom M, Hake AM, Unverzagt FW, Farlow M, Matthews BR, Perkins AJ,
Beck RA, Callahan CM: Implementing innovative models of dementia
care: the healthy aging brain center. Aging Ment Health 2011, 15:13–22.
20. McDonald CJ, Overhage JM, Tierney WM, Dexter PR, Martin DK, Suico JG,
Zafar A, Schadow G, Blevins L, Glazener T, Meeks-Johnson J, Lemmon L,
Warvel J, Porterfield B, Warvel J, Cassidy P, Lindbergh D, Belsito A, Tucker M,
Williams B, Wodniak C: The regenstrief medical record system: a quarter
century experience. Int J Med Inform 1999, 54:225–253.
21. Cai X, Campbell N, Khan B, Callahan C, Boustani M: Chronic anticholinergic
use and the aging brain. Alzheimers Dement 2012:S1552–S5260.
22. Campbell N, Perkins T, Hui S, Khan B, Boustani M: Association of the
prescribing of anticholinergic medications with incident delirium:
a cohort study. J Am Geriatr Soc 2011, 59:S277–S281.
23. Campbell N, Boustani M, Lane K, Gao S, Hendrie H, Khan B, Murrell J,
Unverzagt F, Hake A, Smith-Gamble V, Hall D: Use of anticholinergics and
the risk of cognitive impairment in an African-American population.
Neurology 2010, 75:152–159.
24. Boustani M, Campbell N, Munger S, Maidment I, Fox C: The Impact of
Anticholinergics on the aging brain: A review and practical application.
Aging Health 2008, 4:311–320.
25. Cummings JL: The Neuropsychiatric Inventory: assessing psychopathology
in dementia patients. Neurology 1997, 48(Suppl 6):S10–S16.
26. Monahan PO, Boustani MA, Alder C, Galvin JE, Perkins AJ, Healey P,
Chehresa A, Shepard P, Bubp C, Frame A, Callahan C: Practical clinical tool
to monitor dementia symptoms: the HABC-Monitor. Clin Interv Aging
2012, 7:143–157.
27. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM,
Nikoloff DM, Wu L, Hillman G, Hayes DF, Stearns V, Flockhart DA:
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen
metabolism: implication for optimization of breast cancer treatment.
Clin Pharmacol Ther 2006 Jul, 80:61–74.
28. Borges S, Desta Z, Jin Y, Faouzi A, Robarge JD, Philip S, Nguyen A, Stearns V,
Hayes D, Rae JM, Skaar TC, Flockhart DA, Li L: A composite functional
genetic and co-medication CYP2D6 activity score in predicting
tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol
2010, 50:450–458.
29. Miao J, Jin Y, Marunde RL, Kim S, Quinney S, Radovich M, Li L, Hall SD:
Association of genotypes of the CYP3A cluster with midazolam
disposition in vivo. Pharmacogenomics J 2009, 9:319–326.
30. Ward BA, Morocho A, Kandil A, Galinsky RE, Flockhart DA, Desta Z:
Characterization of human cytochrome P450 enzymes catalyzing
domperidone N-dealkylation and hydroxylation in vitro. Br J Clin
Pharmacol 2004, 58:277–287.
doi:10.1186/1745-6215-14-125
Cite this article as: Campbell et al.: Medication adherence and
tolerability of Alzheimer’s disease medications: study protocol for a
randomized controlled trial. Trials 2013 14:125.

Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit

